Literature DB >> 21298771

Red cell exchange does not appear to increase the rate of allo- and auto-immunization in chronically transfused children with sickle cell disease.

Lakshmi Venkateswaran1, Jun Teruya, Christy Bustillos, Donald Mahoney, Brigitta U Mueller.   

Abstract

BACKGROUND: Allo- and auto-antibody development is a well recognized complication of chronic red cell transfusion (RCT) in sickle cell disease (SCD). Limited matching of Rh (C, c, D, E, e) and K red cell antigens reduces the incidence of immunization. PROCEDURE: We reviewed our experience with red cell allo- and auto-immunization in pediatric SCD patients receiving chronic and/or exchange transfusions, to evaluate the rate of immunization after limited red cell antigen matching and specifically during red cell exchange (RCE) transfusion. A retrospective chart review of the patients with SCD followed at our center between 2002 and 2006, who were started on chronic RCT before or during that time period, was conducted.
RESULTS: Of the 93 patients who met study criteria, 23 (24%) developed antibodies during chronic red cell transfusions. Thirty-four antibodies (15 auto-antibodies, 18 allo-antibodies) developed after the institution of limited red cell antigen matching. The rate of allo- and auto-immunization per unit of red cell exposure after limited phenotyping was 1.5%, comparable to other published data. Fifteen patients underwent RCE, utilizing a total of 2,289 packed red cell units. None developed antibodies during RCE.
CONCLUSION: We conclude that limited red cell antigen matching is an effective strategy for reducing the incidence of allo- and auto-immunization in chronically transfused children with SCD. RCE does not appear to increase the risk of allo- or auto-immunization, despite exposure to more red cell units.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21298771     DOI: 10.1002/pbc.22985

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

Review 1.  Transfusion in Haemoglobinopathies: Review and recommendations for local blood banks and transfusion services in Oman.

Authors:  Arwa Z Al-Riyami; Shahina Daar
Journal:  Sultan Qaboos Univ Med J       Date:  2018-04-04

Review 2.  Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease.

Authors:  Eric A Gehrie; Paul M Ness; Evan M Bloch; Seema Kacker; Aaron A R Tobian
Journal:  Transfusion       Date:  2017-06-26       Impact factor: 3.157

Review 3.  Transfusion medicine problems and solutions for the pediatric hematologist/oncologist.

Authors:  Naomi L C Luban; Eileen McBride; Jason C Ford; Sumit Gupta
Journal:  Pediatr Blood Cancer       Date:  2012-01-11       Impact factor: 3.167

4.  Economic evaluation of a hypothetical screening assay for alloimmunization risk among transfused patients with sickle cell disease.

Authors:  Seema Kacker; Paul M Ness; William J Savage; Kevin D Frick; R Sue Shirey; Karen E King; Aaron A R Tobian
Journal:  Transfusion       Date:  2014-02-27       Impact factor: 3.157

Review 5.  Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease.

Authors:  Yan Zheng; Stella T Chou
Journal:  Clin Lab Med       Date:  2020-12-24       Impact factor: 1.935

6.  Red cell transfusion and alloimmunization in sickle cell disease.

Authors:  Grace E Linder; Stella T Chou
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

7.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

8.  Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country.

Authors:  B F Faye; D Sow; M Seck; N Dieng; S A Toure; M Gadji; A B Senghor; Y B Gueye; D Sy; A Sall; T N Dieye; A O Toure; S Diop
Journal:  Adv Hematol       Date:  2017-05-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.